Long
BLUE has bottomed
Love it or hate it, it's BLUE.
Anecdotal, non-scientific evidence of a serious side effect prompted a halt of a trial of a product, and the company is investigating. No one knows anything else until the company reports. End. Of. Story.
There is a strong bid today, and here you can see why. BLUE has clipped long-term support and bounced nicely off of it for it's largest intraday gain in (what seems like) a long time.
My bet is that BLUE now remains in this ascending channel, which should entail some enjoyable rallies and frustrating pullbacks. You can sell $20/$25 put spreads and sleep at night, and the gamblers among you can buy calls in the upper half of the channel.
Bon voyage, BLUE.
Anecdotal, non-scientific evidence of a serious side effect prompted a halt of a trial of a product, and the company is investigating. No one knows anything else until the company reports. End. Of. Story.
There is a strong bid today, and here you can see why. BLUE has clipped long-term support and bounced nicely off of it for it's largest intraday gain in (what seems like) a long time.
My bet is that BLUE now remains in this ascending channel, which should entail some enjoyable rallies and frustrating pullbacks. You can sell $20/$25 put spreads and sleep at night, and the gamblers among you can buy calls in the upper half of the channel.
Bon voyage, BLUE.
Thông báo miễn trừ trách nhiệm
Thông tin và các ấn phẩm này không nhằm mục đích, và không cấu thành, lời khuyên hoặc khuyến nghị về tài chính, đầu tư, giao dịch hay các loại khác do TradingView cung cấp hoặc xác nhận. Đọc thêm tại Điều khoản Sử dụng.
Thông báo miễn trừ trách nhiệm
Thông tin và các ấn phẩm này không nhằm mục đích, và không cấu thành, lời khuyên hoặc khuyến nghị về tài chính, đầu tư, giao dịch hay các loại khác do TradingView cung cấp hoặc xác nhận. Đọc thêm tại Điều khoản Sử dụng.